SCHEMBL4953157

SCHEMBL4953157

COc1ccccc1C1CC(O)c2cc(O)ccc2O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP19A1 P11511 2/20 0.44
PTPN1 P18031 2/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CYP3A4 P08684 2/20 0.39
AR P10275 1/20 0.39
ESR1 P03372 2/20 0.38
ESR2 Q92731 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361580 0.80 AR (0.41) ALDH1A1CYP19A1MAOBCYP3A4AR
SCHEMBL4363521 0.80 AR (0.41) MAOAMAOBCYP3A4ARESR1
SCHEMBL4365834 0.78 AR (0.54) ALDH1A1MEN1KMT2ACYP19A1MAOA
SCHEMBL4953164 0.78 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ACYP19A1MAOB
SCHEMBL4359940 0.78 CYP19A1 (0.49) ALDH1A1MEN1KMT2ACYP19A1CYP3A4
SCHEMBL27517062 0.77 ESR2 (0.57) ALDH1A1MEN1KMT2ACYP19A1PTPN1
SCHEMBL4364935 0.77 ESR1 (0.41) CYP3A4ARESR1ESR2HTR2A
SCHEMBL4373725 0.75 AR (0.37) CYP19A1CYP3A4ARESR1ESR2
SCHEMBL4951987 0.75 AR (0.71) ALDH1A1MEN1KMT2ACYP19A1PTPN1
SCHEMBL4366070 0.75 AR (0.40) ALDH1A1MEN1KMT2ACYP19A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425568-B2 Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias ORION CORPORATION (FI) 2008-09-16 US disclosed
EP-1412343-B1 COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS ORION CORP (FI) 2006-08-30 EP disclosed
US-20040235905-A1 Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias ORION CORPORATION (FI) 2004-11-25 US disclosed
EP-1412343-A1 NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS ORION CORPORATION (FI) 2004-04-28 EP disclosed
WO-2003006452-A1 NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS ORION CORPORATION (FI) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235905-A1 Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias CACNA1E, KCNN4, RYR2 ALDH1A1 4382/4885MEN1 4334/4885KMT2A 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.